Olga Mulas

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission

Monica Bocchia, Anna Sicuranza, Elisabetta Abruzzese et al. · Frontiers in Oncology · 2018 · 105 citations · Full text

Medicine, Hematology, Oncology +17

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart

Giovanni Caocci, Olga Mulas, Elisabetta Abruzzese et al. · Hematological Oncology · 2019 · 70 citations · Full text

Medicine, Cardiology, Hematology +16

Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients

Giovanni Caocci, Bruno Martino, Marianna Greco et al. · Experimental Hematology · 2015 · 56 citations

Medicine, Hematology, Oncology +15

Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients

Giorgio La Nasa, Giovanni Caocci, Roberto Littera et al. · Experimental Hematology · 2013 · 34 citations

Medicine, Hematology, Oncology +17

Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors

Giovanni Caocci, Olga Mulas, Mario Annunziata et al. · International Journal of Cardiology · 2019 · 27 citations · Full text

Medicine, Oncology, Pharmacology +16